Five questions for Novartis India's MD
This article was originally published in Scrip
Novartis India's vice chairman and managing director Ranjit Shahani once joked that almost every passenger even on a "Virar fast local" knows about the company and its anticancer, Glivec (imatinib mesylate), with the backdrop of the Supreme Court ruling last year rejecting a patent for the product and high decibel allegations by activists that the Swiss company was attempting to get the legal framework for examining patent applications in India relaxed.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.